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Figure: Percentage of features with ICC>0.9 for CT1 vs. CBCT-
1 and CBCT-1 vs. CBCT-2, displayed for each feature group.  
 
Conclusion: For 26% of the radiomics features there is good 
agreement between CT1 and CBCT. 81% of the image 
features show high correlation between CBCT-FX1 and CBCT-
FX2 where no large differences are expected. In the future, 
radiomic features derived from CBCT images will be 
investigated to monitor changes of CBCT features over the 
course of treatment. One has to be careful with mixing 
radiomic features derived on planning CT and CBCT scans. 
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Purpose or Objective: Tumour sub-volumes for dose 
escalation can be defined using different PET tracers. This 
study compares hypoxic volumes defined by FMISO PET and 
metabolically active volumes defined by FDG PET for patients 
with advanced squamous cell carcinomas of the head and 
neck (SCCHN). 
 
Material and Methods: Imaging data of 14 patients was used, 
which were included in a phase II FMISO dose escalation 
study. Pre-therapy FMISO PET/CT images were acquired four 
hours post tracer injection. FDG PET/CT imaging was 
performed according to the institutional diagnostic protocol. 
The planning CT and the GTV of the primary tumour were 
available. Datasets were deformably co-registered using the 
CT images. Metabolically active sub-volumes were segmented 
in FDG PET images based on a source-to-background method 
with an adaptive threshold. Hypoxic sub-volumes were 
defined using a tumour-to-muscle threshold of 1.4. Expanding 
the volumes by an isotropic margin of five millimeters 
resulted in PTV-prim and potential dose escalation volumes 
PTV-FMISO and PTV-FDG. We analyzed the overlap between 
PTV-FMISO and PTV-FDG. 
 
Results: Mean dose escalation volumes were 19.7 cm³ (0.0-
57.3 cm³) for PTV-FMISO and 39.3 cm³ (17.5-91.9 cm³) for 
PTV-FDG. On average PTV-FDG covered 73.5% of PTV-FMISO 
(4.9-100.0%). Only for two out of fourteen patients (14%) 
PTV-FMISO was completely covered by PTV-FDG. Vice versa 
36.3% of PTV-FDG overlapped with PTV-FMISO (0.0-97.4%). 
PTV-prim from treatment planning was 111.1 cm³ (57.1-201.2 
cm³). Detailed results of the overlap analysis for all patients 
are given in Table 1. 
 
 
Conclusion: PTV-FDG typically covers PTV-FMISO only 
partially and is on average two times larger. Therefore, a 
dose escalation in the metabolically active sub-volume 
partially misses the hypoxic sub-volume. The large volume 
difference suggests that a substantially higher dose 
escalation is feasible in PTV-FMISO than in PTV-FDG. Clinical 
trials are required to compare the efficacy of both methods. 
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Purpose or Objective: Patients with locally advanced rectal 
cancer (LARC) are commonly treated with neoadjuvant 
chemoradiotherapy (CRT) followed by radical surgery. 
However, tumor responses vary considerably and about one 
third of the patients experience poor disease outcome due to 
metastatic progression. We aimed to investigate if apparent 
diffusion coefficients (ADCs) quantified from diffusion-
weighted MRI (DWMRI) predicted histologic tumor response to 
the neoadjuvant treatment and long-term survival. 
Recognizing the tumor heterogeneity we specifically aimed to 
explore if histogram analysis of tumor ADC may reveal more 
useful information than the commonly used mean ADC 
measure. 
 
Material and Methods: Data from 23 prospectively enrolled 
patients receiving induction neoadjuvant chemotherapy 
(NACT) followed by CRT and radical surgery was analyzed. 
DWMRI was acquired at baseline and after NACT. Tumor 
volumes contoured in T2-weighted MR images were 
transferred to tumor ADC maps calculated with b-values 300 
and 900 s/mm2, before ADCs were extracted from all tumor 
voxels and presented as histograms. The predictive 
information contained in the histograms was evaluated using 
receiver operating characteristic (ROC) curve analysis of each 
percentile from 1-100. Study endpoints were histologic tumor 
regression grade (TRG) and 5-year progression-free survival 
(PFS). 
 
Results: Using the change in tumor ADC from baseline to 
NACT completion, we identified a histogram area below 
median (20th–40th percentiles) to be associated with both 
TRG and PFS. By using the 20th percentile, an increase in 
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ADC predicted poor histologic tumor response (TRG3–5 versus 
TRG1–2) with 91% sensitivity and 83% specificity (area under 
curve (AUC)=0.89, 95% confidence interval (CI)=0.74–1.0, 
p=0.001). Using the 30th percentile, an increase in ADC 
predicted poor PFS with 89% sensitivity and 71% specificity 
(AUC=0.75, 95% CI=0.54–0.95, p=0.051). Univariate regression 
analysis also revealed that the ADC increase was significantly 
associated to poor PFS (hazard ratio=9.7, 95% CI=1.21-78.30, 
p=0.033). 
 
Conclusion: By ADC histogram analysis of DWMRI acquired 
during NACT of LARC we identified low histogram percentiles 
as predictive of histologic tumor response in particular, but 
also long-term survival. The results require validation in 
larger, independent cohorts, but are promising for 
identification of patients that may benefit from 
individualized treatment approaches for improved disease 
outcome. 
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Purpose or Objective: Tumor hypoxia is prognostic for poor 
outcome after radiotherapy (RT). A method for non-invasive 
assessment of hypoxia is PET using hypoxia radiotracers such 
as FMISO. The goal of this study was to develop and evaluate 
a tool to simulate 3D oxygen distribution and the resulting 
FMISO accumulation on realistic vessel architectures, which 
can be compared to measured PET activities in small animal 
experiments. 
 
Material and Methods: Two FaDu tumors (human HNSCC) 
were grown on the right hind leg of nude mice. Imaging was 
performed after a growth phase of about 5 weeks. FMISO was 
injected into the tail vein of the anesthetized mice with an 
activity of ~12MBq for dynamic PET/MRI. ROIs inside the left 
ventricle and in the tumor were chosen to determine blood 
and tumor time activity curves (TACs). After image 
acquisition tumors were excised, snap frozen and cut into 
consecutive sections (20µm). Sections were stained with 
immunoflourescence-labeled antibodies for endothelial 
marker CD31 and scanned with a Zeiss Axioplan 2 
fluorescence microscope. Obtained immunofluorescence 
images were rigidly registered, manually adjusted and 
thresholded to create a binary 3D vessel map. These maps 
were used to simulate 3D oxygen distributions based on a 
Michaelis-Menten relation. Using the oxygen distribution and 
the dynamic activity in the left ventricle as input, FMISO 
retention was simulated on the same vessel maps. A tumor 
ROI was selected and its average activity at different time 
points post-injection (p.i.) compared against the measured 
activity in the same region on the PET scan (tumor TAC). To 
compare 3D and 2D simulations, the simulation were 
repeated in 2D on the individual sections, and 2D-based 
oxygen histograms and TACs were determined. 
 
Results: O2 histograms showed a large difference between 
2D and 3D simulations, with much lower values for 2D 
simulations than for 3D (5.94 mmHg vs 26.57 mmHg). Mean 
values were closer together (8.9 mmHg vs 13.2 mmHg). This 
is due to the large amount of anoxic voxels (pO2 < 1 mmHg) 
in the 2D simulation, which made up 17.5% of all simulated 
voxels in 2d, but less than 1% in the 3D simulations (see Table 
1). Visually, the 3D simulations result in a TAC with a similar 
overall shape compared to the TAC measured with small 
animal PET, but with a 20.7% overestimation of activity. 
However, the 2D simulations severely overestimated the total 
activity by 99.2% (2D) when compared against measured 
activity in the tumor after 90min as determined by PET. 
 
 
Conclusion: 3D simulations based on real 3D vessel 
architecture is feasible. Our FMISO simulations showed large 
discrepancies between 2D and 3D simulation approaches, 
with the 3D values being closer to the PET measurements. 
Verification of 3D tracer accumulation patterns in additional 
tumors against pimonidazole stainings is still necessary to 
validate and calibrate the method, with PET scans in the 
same test subject to confirm observed activity. 
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Purpose or Objective: Tumorcontrol of primary prostate 
cancer (PC) is dose dependent. Dominant index lesions (DIL) 
within the prostatic gland are responsible for local and 
distant failure. Radionuclide-labelled inhibitors of prostate-
specific membrane antigen (PSMA-PET) showed promising 
preclinical and clinical results in detection of primary 
prostate cancer. We correlated PET/histopathology using a 
new coregistration approach, which allows pixel-wise 
evaluation of the tracers performance in prostatic tissue. Aim 
of this work is to evaluate the diagnostic accuracy of 68Ga-
PSMA-PET/CT and to determine potential SUV-thresholds 
enabling a focal dose escalation on DIL delineated by PET. 
 
Material and Methods: 10 patients with primary PC and 
68Ga-PSMA-PET/CT were enrolled. After prostatectomy, 
thorough histopathological preparation and anatomical-based 
coregistration between in-vivo and ex-vivo material was 
performed. Simulated PET-images were generated out of 
blurred 3D histopathological tumor distribution (histoPET). 
The coregistration was further optimized by matching 
histoPET information with the in-vivo PET signal. The tracer 
performance was evaluated by coefficient of determination 
(R²) between histoPET/PSMA-PET patterns and SUV-values 
within different tissue types. 
 
Results: 1 patient was excluded due to imprecise 
pathological preparation. Mean R² value was 60 % (± SD 15.2, 
range: 42.5-81.6). SUVmax of PSMA-PET was located in non 
resolution adapated / resolution adapted PC-tissue in 
80%/90% of patients. Mean SUVmean in non resolution 
adapted PC and non-PC tissue was 6.1 (range: 2 – 21) and 2.7 
(range: 1.3 – 8.2), respectively. The ratio between SUVmean 
in PC / non-PC was 2.2 (SD ± 0.6). 
 
